TB-500 Peptide Research: The Science Behind Thymosin Beta-4

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Known as Thymosin beta-4 (Thymosin β4 or Tβ4), TB-500 has drawn considerable interest in regenerative investigations. Researchers are keen on its distinct biological attributes. This peptide, composed of 43 amino acids, first came from calf thymus and is now a primary subject in tissue repair and regeneration research.

At a molecular level, the peptide has an N-terminal acetylated group essential for its biological work. Its molecular weight is roughly 4.9 kilodaltons. TB-500’s strong preservation across mammalian species points to its fundamental significance in biological functions.

Key Research Insights

• TB-500 functions as the major G-actin sequestrating molecule in cells, controlling actin polymerization processes that drive cellular migration and tissue repair
• The peptide contains distinct functional fragments with specialized roles, from anti-inflammatory effects to cell migration enhancement
• Research spans multiple organ systems including cardiac tissue, neurological applications, and wound healing models
• Studies show TB-500 works through both immediate protective mechanisms and longer-term regenerative pathways across different research applications

TB-500 Peptide Structure and Mechanisms

TB-500 consists of 43 amino acid residues[1] with a molecular weight of 4,982 Da and an isoelectric point of 5.1. The peptide’s structure features a blocked N-terminus through acetylation, which research shows is essential for proper function.

The peptide operates primarily through G-actin sequestration[2], making it the major monomeric actin-sequestering molecule in eukaryotic cells. This mechanism allows TB-500 to regulate actin polymerization and depolymerization, processes that are central to cellular migration and tissue repair.

Key Structural Features:

• 43 amino acid residues
• Molecular weight: 4,982 Da
• Isoelectric point: 5.1
• N-terminal acetylation required for activity

Research has identified several active fragments within the TB-500 sequence[3], each with distinct biological properties:

Fragment	Amino Acids	Primary Activity
1-4	N-terminal	Anti-inflammatory
1-15	N-terminal	Anti-apoptotic and cytoprotective
17-23	Central	Cell migration and wound healing

? Free TB-500 Research Guide + Exclusive Offers

Subscribe to our community and get a free PDF download that covers everything research professionals need to know about TB-500, plus exclusive discounts and promotions.

Cardiovascular Research Applications

TB-500 has been extensively studied in cardiovascular research, with animal models showing promising results across multiple cardiac conditions. The peptide appears to work through both immediate protective mechanisms and longer-term regenerative pathways.

Cardiac Tissue Studies

TB-500 has shown notable effects in cardiovascular research models. Studies show the peptide works through a dual-phase mechanism in myocardial infarction models[4]. The acute phase involves preserving ischemic tissue through anti-apoptotic mechanisms, while the chronic phase activates progenitor cells.

Research indicates TB-500 reduces infarct size and improves contractile performance in chronic myocardial ischemic injury models[4]. The peptide promotes neovascularization and improves cardiac function in both normal and hypercholesterolemic animal models[5].

Molecular Pathways in Cardiac Research

Recent studies have identified specific molecular pathways through which TB-500 affects cardiac tissue:

• ROCK1 modulation: TB-500 regulates ROCK1 expression in cardiac remodeling studies[6]
• miRNA regulation: The peptide influences miR139-5p expression patterns
• Epicardial activation: TB-500 reactivates embryonic developmental programs in epicardial tissue[7]

A Phase I clinical trial in healthy volunteers demonstrated that recombinant human TB-500 showed good tolerability profiles across various concentrations[8].

Neurological Research Findings

TB-500 has been studied across multiple neurological conditions, with research spanning traumatic brain injury, stroke, and neurodegenerative diseases. The peptide appears to offer both acute protective effects and longer-term regeneration effects.

Traumatic Brain Injury Models

TB-500 has demonstrated significant neuroprotective and neuroregenerative effects in traumatic brain injury research[9]. Studies show both acute neuroprotection and long-term neurorestoration.

The peptide promotes several beneficial effects in brain injury models:

• Better neurogenesis
• Improved angiogenesis
• Reduced brain lesion volume
• Better functional recovery outcomes

Stroke Research Models

Multiple studies have evaluated TB-500’s effects in stroke models[10]. The peptide improves neurological outcomes through oligodendrogenesis, promoting the formation of new oligodendrocytes[9]. Research also shows better axonal remodeling and reduced neuroinflammation.

A dose-response study identified optimal therapeutic windows for stroke treatment[11], showing that TB-500 administration 24 hours after stroke onset improved functional outcomes.

Multiple Sclerosis Research

In experimental autoimmune encephalomyelitis (EAE) models, TB-500 improved neurological function by reducing inflammatory infiltrates and stimulating oligodendrogenesis[12]. The peptide’s ability to promote myelin repair makes it a research target for demyelinating diseases.

Related Product: Buy TB-500 for laboratory research use.

Wound Healing and Tissue Regeneration Studies

TB-500 has been studied extensively in wound healing research, with studies covering both dermal and corneal applications. The peptide appears to work through multiple pathways to speed healing and reduce inflammation.

Dermal Wound Research

TB-500 accelerates dermal wound healing through multiple mechanisms in research models[13]. Studies show the peptide improves re-epithelialization, improves vascular density, reduces inflammation, and accelerates tissue remodeling.

Research shows that topical TB-500 application reduces healing time by approximately one day compared to controls[14]. The peptide’s effects are particularly pronounced in diabetic wound healing models, where it overcomes the impaired healing typically associated with diabetes.

Corneal Wound Studies

Extensive research has established TB-500’s effects in corneal wound healing models[15]. The peptide promotes rapid corneal re-epithelialization, reduces polymorphonuclear leukocyte infiltration, and decreases inflammatory mediator expression[16].

Anti-inflammatory Effects in Research:

• Downregulates interleukin-1β (IL-1β)
• Reduces macrophage inflammatory proteins (MIP-1α, MIP-1β, MIP-2)
• Decreases monocyte chemoattractant protein-1 (MCP-1)

Clinical Research Progress

TB-500 has progressed through multiple phases of clinical trials, with ophthalmic applications showing the most advanced development. Current research focuses on safety profiles and therapeutic windows.

Ophthalmic Research

Phase II clinical trials have evaluated TB-500 ophthalmic solution for dry eye. A randomized, placebo-controlled study of 72 subjects showed a 27% reduction in discomfort scores and improvements in corneal staining[17].

The research showed an excellent safety profile with no adverse events reported during the study period.

Current Clinical Development

Phase III clinical trials are currently ongoing for several ophthalmic applications:

• Dry eye treatment
• Neurotrophic keratopathy
• Corneal wound healing disorders

Multiple clinical studies have established TB-500’s safety profile across different research contexts[18].

Emerging Research Areas

Research into TB-500 continues to expand into new areas, with studies exploring metabolic disorders, infectious diseases, and cancer biology. These newer applications show the peptide’s versatility across different biological systems.

Metabolic Research

Research indicates TB-500’s potential in metabolic syndrome studies[19]. Serum TB-500 levels serve as a biomarker for non-alcoholic fatty liver disease research, while studies show the peptide improves endothelial function in diabetic research models[20].

Infectious Disease Research

Recent studies suggest TB-500’s potential in viral infection research[21]. Research shows improved survival rates in coronavirus-infected animal models and enhanced antimicrobial response in bacterial infection studies[22].

Cancer Biology Research

Emerging evidence indicates TB-500’s complex role in cancer biology research. Studies show the peptide acts as an iron chelator and molecular switcher in ferroptosis regulation[23], while reduced expression correlates with poor prognosis in certain cancer research models[24].

Research Applications and Future Directions

Current research is expanding TB-500 applications through improved delivery methods and combination approaches. Scientists are also exploring the peptide’s potential as a diagnostic tool.

Technological Research Advances

Research is exploring novel delivery systems[25] for TB-500:

• Nanoparticle formulations for targeted delivery
• Sustained-release systems for prolonged effects
• Combination therapies with other regenerative compounds

Biomarker Research

TB-500 levels are being investigated as diagnostic and prognostic biomarkers. Research shows elevated levels in heart failure patients[26] and reduced levels in NAFLD patients, suggesting potential applications in treatment monitoring.

In Vitro Research Applications

For research laboratories, TB-500 offers several potential applications:

• Cell migration studies: Investigating actin polymerization mechanisms
• Wound healing assays: Evaluating re-epithelialization processes
• Cardiovascular research: Studying cardiac tissue repair mechanisms
• Neurological studies: Examining neuroprotective pathways
• Anti-inflammatory research: Analyzing cytokine regulation

Research institutions continue to explore TB-500’s mechanisms across multiple biological systems, making it a valuable compound for laboratories studying tissue repair, cellular migration, and regenerative processes.

---

---

References

1. Low, T. L., Hu, S. K., & Goldstein, A. L. (1981). Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proceedings of the National Academy of Sciences of the United States of America, 78(2), 1162–1166. https://doi.org/10.1073/pnas.78.2.1162.
2. Xiong, Y., Mahmood, A., Meng, Y., Zhang, Y., Zhang, Z. G., Morris, D. C., & Chopp, M. (2012). Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Annals of the New York Academy of Sciences, 1270, 51–58. https://doi.org/10.1111/j.1749-6632.2012.06683.x.
3. Sosne, G., & Berger, E. A. (2023). Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis. International immunopharmacology, 118, 109953. https://doi.org/10.1016/j.intimp.2023.109953.
4. Bao, W., Ballard, V. L., Needle, S., Hoang, B., Lenhard, S. C., Tunstead, J. R., Jucker, B. M., Willette, R. N., & Pipes, G. T. (2013). Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury. Frontiers in pharmacology, 4, 149. https://doi.org/10.3389/fphar.2013.00149.
5. Ziegler, T., Bähr, A., Howe, A., Klett, K., Husada, W., Weber, C., Laugwitz, K. L., Kupatt, C., & Hinkel, R. (2018). Tβ4 Increases Neovascularization and Cardiac Function in Chronic Myocardial Ischemia of Normo- and Hypercholesterolemic Pigs. Molecular therapy : the journal of the American Society of Gene Therapy, 26(7), 1706–1714. https://doi.org/10.1016/j.ymthe.2018.06.004.
6. Maar, K., Thatcher, J. E., Karpov, E., Rendeki, S., Gallyas, F., Jr, & Bock-Marquette, I. (2025). Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals. International journal of molecular sciences, 26(9), 4131. https://doi.org/10.3390/ijms26094131.
7. Bock-Marquette, I., Shrivastava, S., Pipes, G. C., Thatcher, J. E., Blystone, A., Shelton, J. M., Galindo, C. L., Melegh, B., Srivastava, D., Olson, E. N., & DiMaio, J. M. (2009). Thymosin beta4 mediated PKC activation is essential to initiate the embryonic coronary developmental program and epicardial progenitor cell activation in adult mice in vivo. Journal of molecular and cellular cardiology, 46(5), 728–738. https://doi.org/10.1016/j.yjmcc.2009.01.017.
8. Wang, X., Liu, L., Qi, L., Lei, C., Li, P., Wang, Y., Liu, C., Bai, H., Han, C., Sun, Y., & Liu, J. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of cellular and molecular medicine, 25(17), 8222–8228. https://doi.org/10.1111/jcmm.16693.
9. Xiong, Y., Zhang, Y., Mahmood, A., Meng, Y., Zhang, Z. G., Morris, D. C., & Chopp, M. (2012). Neuroprotective and neurorestorative effects of thymosin β4 treatment initiated 6 hours after traumatic brain injury in rats. Journal of neurosurgery, 116(5), 1081–1092. https://doi.org/10.3171/2012.1.JNS111729.
10. Morris, D. C., Cui, Y., Cheung, W. L., Lu, M., Zhang, L., Zhang, Z. G., & Chopp, M. (2014). A dose-response study of thymosin β4 for the treatment of acute stroke. Journal of the neurological sciences, 345(1-2), 61–67. https://doi.org/10.1016/j.jns.2014.07.006.
11. Zhang, J., Zhang, Z. G., Morris, D., Li, Y., Roberts, C., Elias, S. B., & Chopp, M. (2009). Neurological functional recovery after thymosin beta4 treatment in mice with experimental auto encephalomyelitis. Neuroscience, 164(4), 1887–1893. https://doi.org/10.1016/j.neuroscience.2009.09.054.
12. Ti, D., Hao, H., Xia, L., Tong, C., Liu, J., Dong, L., Xu, S., Zhao, Y., Liu, H., Fu, X., & Han, W. (2015). Controlled release of thymosin beta 4 using a collagen-chitosan sponge scaffold augments cutaneous wound healing and increases angiogenesis in diabetic rats with hindlimb ischemia. Tissue engineering. Part A, 21(3-4), 541–549. https://doi.org/10.1089/ten.TEA.2013.0750.
13. Xu, T. J., Wang, Q., Ma, X. W., Zhang, Z., Zhang, W., Xue, X. C., Zhang, C., Hao, Q., Li, W. N., Zhang, Y. Q., & Li, M. (2013). A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing. Drug design, development and therapy, 7, 1075–1088. https://doi.org/10.2147/DDDT.S50183.
14. Sosne G. (2018). Thymosin beta 4 and the eye: the journey from bench to bedside. Expert opinion on biological therapy, 18(sup1), 99–104. https://doi.org/10.1080/14712598.2018.1486818.
15. Sosne, G., Szliter, E. A., Barrett, R., Kernacki, K. A., Kleinman, H., & Hazlett, L. D. (2002). Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental eye research, 74(2), 293–299. https://doi.org/10.1006/exer.2001.1125.
16. Sosne, G., & Ousler, G. W. (2015). Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clinical ophthalmology (Auckland, N.Z.), 9, 877–884. https://doi.org/10.2147/OPTH.S80954.
17. Wang, X., Liu, L., Qi, L., Lei, C., Li, P., Wang, Y., Liu, C., Bai, H., Han, C., Sun, Y., & Liu, J. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of cellular and molecular medicine, 25(17), 8222–8228. https://doi.org/10.1111/jcmm.16693.
18. Ahmed, A. E., Ibrahim, W. A., Nabil, Z. M., Mansour, K. A., Mansour, A. M. F., & ElGhandour, A. M. (2022). Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients. The Egyptian journal of immunology, 29(2), 76–86.
19. Su, L., Kong, X., Loo, S., Gao, Y., Liu, B., Su, X., Dalan, R., Ma, J., & Ye, L. (2022). Thymosin beta-4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells. Stem cell research & therapy, 13(1), 13. https://doi.org/10.1186/s13287-021-02687-x.
20. Yu, R., Mao, Y., Li, K., Zhai, Y., Zhang, Y., Liu, S., Gao, Y., Chen, Z., Liu, Y., Fang, T., Zhao, M., Li, R., Xu, J., & Chen, W. (2021). Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection. Mediators of inflammation, 2021, 9979032. https://doi.org/10.1155/2021/9979032.
21. Wang, Y., Banga, L., Ebrahim, A. S., Carion, T. W., Sosne, G., & Berger, E. A. (2024). Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4 during Pseudomonas aeruginosa-induced keratitis. Frontiers in immunology, 15, 1458684. https://doi.org/10.3389/fimmu.2024.1458684.
22. Lachowicz, J. I., Pichiri, G., Piludu, M., Fais, S., Orrù, G., Congiu, T., Piras, M., Faa, G., Fanni, D., Dalla Torre, G., Lopez, X., Chandra, K., Szczepski, K., Jaremko, L., Ghosh, M., Emwas, A. H., Castagnola, M., Jaremko, M., Hannappel, E., & Coni, P. (2022). Thymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis. International journal of molecular sciences, 23(1), 551. https://doi.org/10.3390/ijms23010551.
23. Yu, R., Gao, D., Bao, J., Sun, R., Cui, M., Mao, Y., Li, K., Hu, E., Zhai, Y., Liu, Y., Gao, Y., Xiao, T., Zhou, H., Yang, C., & Xu, J. (2023). Exogenous Thymosin Beta 4 Suppresses IPF-Lung Cancer in Mice: Possibly Associated with Its Inhibitory Effect on the JAK2/STAT3 Signaling Pathway. International journal of molecular sciences, 24(4), 3818. https://doi.org/10.3390/ijms24043818.
24. Huang, Z., Song, Y., Pang, Z., Zhang, B., Yang, H., Shi, H., Chen, J., Gong, H., Qian, J., & Ge, J. (2017). Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles. International journal of nanomedicine, 12, 3023–3036. https://doi.org/10.2147/IJN.S131949.
25. Drum, C. L., Tan, W. K. Y., Chan, S. P., Pakkiri, L. S., Chong, J. P. C., Liew, O. W., Ng, T. P., Ling, L. H., Sim, D., Leong, K. G., Yeo, D. P. S., Ong, H. Y., Jaufeerally, F., Wong, R. C. C., Chai, P., Low, A. F., Davidsson, P., Liljeblad, M., Söderling, A. S., Gan, L. M., … Richards, A. M. (2017). Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 6(6), e005586. https://doi.org/10.1161/JAHA.117.005586.